1. Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature)
- Author
-
Marianna Makowska, Hanna Romanowicz, and Beata Smolarz
- Subjects
Drug ,GABA receptors ,Candidate gene ,ATP Binding Cassette Transporter, Subfamily B ,Pharmacogenomic Variants ,QH301-705.5 ,media_common.quotation_subject ,Drug Resistance ,Drug resistance ,Disease ,Review ,Bioinformatics ,Catalysis ,Inorganic Chemistry ,Epilepsy ,drug-resistant epilepsy ,CYP2 family ,Medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Biology (General) ,genes ,Molecular Biology ,QD1-999 ,MDR-1 ,Spectroscopy ,media_common ,pharmacogenetics ,business.industry ,Organic Chemistry ,ion channels ,General Medicine ,Drug Resistant Epilepsy ,medicine.disease ,Computer Science Applications ,Pharmacogenomic Testing ,Chemistry ,Pharmacogenomics ,Inactivation, Metabolic ,business ,Pharmacogenetics - Abstract
Pharmacogenomic studies in epilepsy are justified by the high prevalence rate of this disease and the high cost of its treatment, frequent drug resistance, different response to the drug, the possibility of using reliable methods to assess the control of seizures and side effects of antiepileptic drugs. Candidate genes encode proteins involved in pharmacokinetic processes (drug transporters, metabolizing enzymes), pharmacodynamic processes (receptors, ion channels, enzymes, regulatory proteins, secondary messengers) and drug hypersensitivity (immune factors). This article provides an overview of the literature on the influence of genetic factors on treatment in epilepsy.
- Published
- 2021